Curcumin and its novel formulations for the treatment of hepatocellular carcinoma: New trends and future perspectives in cancer therapy
2023
Seyed Mohammadmahdi Meybodi | Pouria Rezaei | Niki Faraji | Kiyarash Jamehbozorg | Sara Ashna | Fatemeh Shokri | Pouya Goleij | Saeed Moradi | Mahdis Kashian | Reza Arefnezhad | Amirhossein Sahebkar
Hepatocellular carcinoma (HCC), as a common malignancy of the liver, is the second leading cause of cancer-related death in the world and mostly occurs in patients with a background of chronic liver disease. Patents with this carcinoma represent various signs and symptoms, such as splenomegaly, peripheral edema, and jaundice. More than 70 % of HCC cases are in the advanced stage because of lacking the diagnostic systems and indications in the early stages, therefore giving rise to a high lethality rate in involved patients. Against this malignancy, several therapeutic methods have been recommended, like surgical resection, immunotherapy, liver transplantation, and chemotherapeutic drugs (e.g., doxorubicin, mitomycin C, and cisplatin); however, these curative modalities have not created a serious hope for HCC patents. Nowadays, herbal medicine with natural compounds has been offered for different illnesses, such as cancer. Among these, some herbal components and their nano-based formulations, especially curcumin (a polyphenol extract of Curcuma longa), have become a point of interest in treating HCC. Hence, this review aimed to evaluate the anticancer effects of curcumin and its biological potential for treating HCC based on the current documents.
Show more [+] Less [-]AGROVOC Keywords
Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals
